Key result
Blank survey assesses outpatient oral medication administration for pediatric heart disease in Switzerland.
Why the study?
While cardiovascular drug therapy in adults steadily progresses, the extent to which children with heart disease in Switzerland benefit from this progress remains unknown.
Cross-Sectional
Answers are grounded in this paper and cite their sources.
Swiss paediatric cardiologists predominantly rely on established drugs for cardiovascular diseases, with limited use of newer therapies due to lack of child-friendly formulations, authorization, and reimbursement.
UNLABELLED: Cardiovascular drug therapy in adults is steadily progressing. However, the extent to which children with heart disease in Switzerland benefit from this progress remains unknown. This survey aimed to investigate the current outpatient prescribing practices among paediatric cardiologists in Switzerland. We conducted a cross-sectional survey among Swiss paediatric cardiologists. The physicians were asked to state how often they administer drugs on a pre-defined list for the following indications: heart failure, arrhythmia and thromboembolism. Forty-three (56%) out of 77 eligible physicians completed the survey. For paediatric heart failure, the three most frequently prescribed drugs were hydrochlorothiazide ('often prescribed' by n = 25, 58%), lisinopril (n = 24, 56%), and spironolactone (n = 32, 74%). The most frequently prescribed drugs for arrhythmia and thromboembolism were propranolol (n = 26, 60%) and acetylsalicylic acid (n = 31, 72%), respectively. Newer drugs such as sacubitril/valsartan ('never prescribed' by n = 20, 47%), sodium-glucose cotransporter type 2 inhibitors (n = 40, 93%), and direct oral anticoagulants (n = 20, 47%) were rarely used. CONCLUSION: The drugs used to treat heart failure, arrhythmia, and thromboembolism in Switzerland largely reflect current international recommendations. Nevertheless, novel drugs are rarely used. In addition to the lack of large randomized controlled drug trials in children, important obstacles are lack of authorization, lack of reimbursement, and lack of suitable formulations. These issues should be addressed by both the industry and healthcare providers to continuously improve drug therapy for children with heart disease. WHAT IS KNOWN: • Evidence for drug use in Paediatric cardiology mostly relies on extrapolation from adult studies and pathophysiological considerations. • Drug choices are also influenced by drug approval, insurance reimbursement, and availability of age-appropriate formulations. WHAT IS NEW: • Swiss paediatric cardiologists predominantly rely on established drugs to treat cardiovascular diseases in children, with the use of newer drugs remaining limited. • On top of expert consensus, adult evidence, and drug availability, drug prescription appears to be strongly influenced by the availability of child-friendly formulations.
No takes yet. Share an insight, caveat, or question.
Bärlocher et al. (2026) conducted a cross-sectional in Heart disease in children. Oral cardiovascular medications was evaluated. This document is a blank survey questionnaire designed to assess the outpatient administration of oral medications for children with heart disease in Switzerland.
Synapse has enriched 10 related papers. Consider them for comparative context: